blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1930416

EP1930416 - NOVEL RECOMBINANT HUMAN HEPATITIS C VIRUS-LIKE PARTICLE AND METHOD FOR PRODUCING THE SAME [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  19.10.2012
Database last updated on 16.07.2024
Most recent event   Tooltip18.07.2014Lapse of the patent in a contracting state
New state(s): HU		published on 20.08.2014  [2014/34]
Applicant(s)For all designated states
JAPAN AS REPRESENTED BY THE DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES
23-1, Toyama 1-chome
Shinjuku-ku
Tokyo 162-8640 / JP
For all designated states
Tokyo Metropolitan Institute of Medical Science
1-6, Kamikitazawa 2-chome
Setagaya-ku
Tokyo / JP
For all designated states
TORAY INDUSTRIES, INC.
1-1, Nihonbashi Muromachi 2-chome
Chuo-ku
Tokyo 103-8666 / JP
[N/P]
Former [2011/49]For all designated states
JAPAN AS REPRESENTED BY THE DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES
23-1, Toyama 1-chome
Shinjuku-ku
Tokyo 162-8640 / JP
For all designated states
Tokyo Metropolitan Institute of Medical Science
1-6, Kamikitazawa 2-chome
Setagaya-ku
Tokyo / JP
For all designated states
TORAY INDUSTRIES, INC.
1-1, Nihonbashi Muromachi 2-chome
Chuo-ku
Tokyo 103-8666 / JP
Former [2011/46]For all designated states
JAPAN as represented by DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES
23-1, Toyama-cho 1-chome Shinjuku-ku
Tokyo 162-8640 / JP
For all designated states
Tokyo Metropolitan Institute of Medical Science
1-6, Kamikitazawa 2-chome
Setagaya-ku
Tokyo / JP
For all designated states
TORAY INDUSTRIES, INC.
1-1, Nihonbashi-Muromachi 2-chome Chuo-ku
Tokyo 103-8666 / JP
Former [2008/24]For all designated states
JAPAN as represented by DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES
23-1, Toyama-cho 1-chome Shinjuku-ku
Tokyo 162-8640 / JP
For all designated states
Tokyo Metropolitan Organization for Medical Research
8-1, Nishishinjuku 2-chome Shinjuku-ku
Tokyo 163-8001 / JP
For all designated states
TORAY INDUSTRIES, INC.
1-1, Nihonbashi-Muromachi 2-chome Chuo-ku
Tokyo 103-8666 / JP
Inventor(s)01 / TANABE, Jun-ichi, @c/o Pharmaceutical Research Laboratories
Basic Research Laboratories Toray Industries Inc.
1111 Tebiro
Kamakura-shi Kanagawa 248-0036 / JP
02 / SONE, Saburo
1120-3
Yoshida-cho
Totsuka-ku
Yokohama-shi Kanagawa 244-0817 / JP
03 / WAKITA, Takaji, @c/o Department of Virology II, National Institute
of Infectious Diseases, 23-1,Toyama
1-chome, Shinjuku-ku, Tokyo 162-8640 / JP
04 / ISHII, Koji
1-601 Funamachi
Shinjuku-ku
Tokyo160-0006 / JP
05 / SUZUKI, Ryosuke
32-16 Katsutadai 5-chome
Yachiyo-shi Chiba 276-0023 / JP
06 / SUZUKI, Tetsuro
14-15-516 Yagisawa 2-chome
Nishitokyo-shi Tokyo 202-0022 / JP
07 / MIYAMURA, Tatsuo
21-22-113 Hamadayama 4-chome
Suginami-ku Tokyo168-0065 / JP
 [2011/45]
Former [2008/33]01 / TANABE, Jun-ichi, c/o Pharmaceutical Research Laboratories
Basic Research Lab. Toray Industries Inc. 1111 Tebiro
Kamakura-shi Kanagawa 248-0036 / JP
02 / SONE, Saburo
1120-3 Yoshida-cho Totsuka-ku
Yokohama-shi Kanagawa 244-0817 / JP
03 / WAKITA, Takaji, Department of Virology II
Nat. Institute of Infectious Diseases, 23-1,Toyama
1-chome, Shinjuku-ku, Tokyo 162-8640 / JP
04 / ISHII, Koji
1-601 Funamachi Shinjuku-ku
Tokyo160-0006 / JP
05 / SUZUKI, Ryosuke
32-16 Katsutadai 5-chome
Yachiyo-shi Chiba 276-0023 / JP
06 / SUZUKI, Tetsuro
14-15-516 Yagisawa 2-chome
Nishitokyo-shi Tokyo 202-0022 / JP
07 / MIYAMURA, Tatsuo
21-22-113 Hamadayama 4-chome
Nishitokyo-shi Tokyo168-0065 / JP
Former [2008/29]01 / TANABE, Jun-ichi, c/o Pharmaceutical Research Laboratories
Basic Research Lab. Toray Industries Inc. 1111 Tebiro
Kamakura-shi Kanagawa 248-0036 / JP
02 / SONE, Saburo
1120-3 Yoshida-cho Totsuka-ku
Yokohama-shi Kanagawa 244-0817 / JP
03 / WAKITA, Takaji
5-17-205 Narimasu 4-chome Itabashi-ku
Tokyo 175-0094 / JP
04 / ISHII, Koji
1-601 Funamachi Shinjuku-ku
Tokyo160-0006 / JP
05 / SUZUKI, Ryosuke
32-16 Katsutadai 5-chome
Yachiyo-shi Chiba 276-0023 / JP
06 / SUZUKI, Tetsuro
14-15-516 Yagisawa 2-chome
Nishitokyo-shi Tokyo 202-0022 / JP
07 / MIYAMURA, Tatsuo
21-22-113 Hamadayama 4-chome
Nishitokyo-shi Tokyo168-0065 / JP
Former [2008/24]01 / TANABE, Jun-ichi, c/o Pharmaceutical Research Laboratories
Basic Research Lab. Toray Industries Inc. 1111 Tebiro
Kamakura-shi Kanagawa 248-0036 / JP
02 / SONE, Saburo
1120-3 Yoshida-cho Totsuka-ku
Yokohama-shi Kanagawa 244-0817 / JP
03 / WAKITA, Takaji
5-17-205 Narimasu 4-chome Itabashi-ku
Tokyo 175-0094 / JP
04 / ISHII, Koji
1-601 Funamachi Shinjuku-ku
Tokyo160-0006 / JP
05 / SUZUKI, Ryosuke
32-16 Katsutadai 5-chome
Yachiyo-shi Chiba 276-0023 / JP
06 / SUZUKI, Tetsuro
14-15-516 Yagisawa 2-chome
Nishitokyo-shi Tokyo 202-0022 / JP
07 / MIYAMURA, Tatsuo
21-22-113 Hamadayama 4-chome
Nishitokyo-shi Tokyo168-0065 / JP
Representative(s)Kador & Partner Part mbB
Corneliusstraße 15
80469 München / DE
[N/P]
Former [2011/50]Kador & Partner
Corneliusstrasse 15
80469 München / DE
Former [2008/31]Kador & Partner
Corneliusstrasse 15
80469 München / DE
Former [2008/24]Kador & Partner
Corneliusstrasse 15
80469 München / DE
Application number, filing date06810937.029.09.2006
[2008/24]
WO2006JP319573
Priority number, dateJP2005028782530.09.2005         Original published format: JP 2005287825
[2008/24]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2007037429
Date:05.04.2007
Language:JA
[2007/14]
Type: A1 Application with search report 
No.:EP1930416
Date:11.06.2008
Language:EN
[2008/24]
Type: B1 Patent specification 
No.:EP1930416
Date:14.12.2011
Language:EN
[2011/50]
Search report(s)International search report - published on:JP05.04.2007
(Supplementary) European search report - dispatched on:EP10.02.2009
ClassificationIPC:C12N7/00, C12N15/09, C12N7/04
[2009/11]
CPC:
C12N7/00 (EP,US); C12N15/52 (KR); C12N15/10 (KR);
C12N15/86 (EP,US); C12N7/02 (KR); C12N2770/24223 (EP,US);
C12N2770/24243 (EP,US); C12N2770/24252 (EP,US) (-)
Former IPC [2008/24]C12N7/00, C12N15/09
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2008/24]
TitleGerman:NEUES REKOMBINANTES PARTIKEL MIT ÄHNLICHKEIT ZUM MENSCHLICHEN HEPATITIS-C-VIRUS UND VERFAHREN ZUR HERSTELLUNG DAVON[2008/24]
English:NOVEL RECOMBINANT HUMAN HEPATITIS C VIRUS-LIKE PARTICLE AND METHOD FOR PRODUCING THE SAME[2008/24]
French:NOUVELLE PARTICULE HUMAINE RECOMBINEE DE TYPE DU VIRUS DE L'HEPATITE C ET PROCEDE DE PRODUCTION ASSOCIE[2008/24]
Entry into regional phase31.03.2008Translation filed 
31.03.2008National basic fee paid 
31.03.2008Search fee paid 
31.03.2008Designation fee(s) paid 
31.03.2008Examination fee paid 
Examination procedure31.03.2008Examination requested  [2008/24]
08.04.2009Despatch of a communication from the examining division (Time limit: M04)
05.08.2009Reply to a communication from the examining division
23.10.2009Despatch of a communication from the examining division (Time limit: M04)
02.03.2010Reply to a communication from the examining division
01.09.2010Despatch of a communication from the examining division (Time limit: M04)
20.12.2010Reply to a communication from the examining division
01.06.2011Communication of intention to grant the patent
30.09.2011Fee for grant paid
30.09.2011Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  08.04.2009
Opposition(s)17.09.2012No opposition filed within time limit [2012/47]
Fees paidRenewal fee
31.03.2008Renewal fee patent year 03
30.09.2009Renewal fee patent year 04
27.09.2010Renewal fee patent year 05
29.09.2011Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU29.09.2006
AT14.12.2011
CY14.12.2011
CZ14.12.2011
DK14.12.2011
EE14.12.2011
FI14.12.2011
LT14.12.2011
LV14.12.2011
SE14.12.2011
SI14.12.2011
SK14.12.2011
TR14.12.2011
BG14.03.2012
IS14.04.2012
[2014/34]
Former [2014/21]AT14.12.2011
CY14.12.2011
CZ14.12.2011
DK14.12.2011
EE14.12.2011
FI14.12.2011
LT14.12.2011
LV14.12.2011
SE14.12.2011
SI14.12.2011
SK14.12.2011
TR14.12.2011
BG14.03.2012
IS14.04.2012
Former [2013/29]AT14.12.2011
CY14.12.2011
CZ14.12.2011
DK14.12.2011
EE14.12.2011
FI14.12.2011
LT14.12.2011
LV14.12.2011
SE14.12.2011
SI14.12.2011
SK14.12.2011
BG14.03.2012
IS14.04.2012
Former [2013/07]AT14.12.2011
CY14.12.2011
CZ14.12.2011
DK14.12.2011
EE14.12.2011
LT14.12.2011
LV14.12.2011
SE14.12.2011
SI14.12.2011
SK14.12.2011
BG14.03.2012
IS14.04.2012
Former [2012/49]CY14.12.2011
CZ14.12.2011
DK14.12.2011
EE14.12.2011
LT14.12.2011
LV14.12.2011
SE14.12.2011
SI14.12.2011
SK14.12.2011
BG14.03.2012
IS14.04.2012
Former [2012/36]CY14.12.2011
CZ14.12.2011
EE14.12.2011
LT14.12.2011
LV14.12.2011
SE14.12.2011
SI14.12.2011
SK14.12.2011
BG14.03.2012
IS14.04.2012
Former [2012/35]CY14.12.2011
CZ14.12.2011
EE14.12.2011
LT14.12.2011
LV14.12.2011
SE14.12.2011
SI14.12.2011
BG14.03.2012
IS14.04.2012
Former [2012/34]CY14.12.2011
CZ14.12.2011
LT14.12.2011
LV14.12.2011
SE14.12.2011
SI14.12.2011
IS14.04.2012
Former [2012/28]CY14.12.2011
LT14.12.2011
LV14.12.2011
SE14.12.2011
SI14.12.2011
Former [2012/24]LT14.12.2011
LV14.12.2011
SE14.12.2011
SI14.12.2011
Former [2012/20]LT14.12.2011
Documents cited:Search[X]WO2004024904  (INST NAT SANTE RECH MED [FR], et al) [X] 1-13 * The whole document, in particular; page 21, line 11 - page 25, line 25 *;
 [E]EP1721985  (TOKYO METROPOLITAN ORG MED RES [JP], et al) [E] 1-13* The whole document, in particular; paragraphs [0009] - [0013] *;
 [A]  - BLANCHARD EMMANUELLE ET AL, "Hepatitis C virus-like particle morphogenesis", JOURNAL OF VIROLOGY, (200204), vol. 76, no. 8, ISSN 0022-538X, pages 4073 - 4079, XP002512089 [A] 1-13 * the whole document *

DOI:   http://dx.doi.org/10.1128/JVI.76.8.4073-4079.2002
 [T]  - ISHII K ET AL, "Trans-encapsidation of hepatitis C virus subgenomic replicon RNA with viral structure proteins", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 371, no. 3, ISSN 0006-291X, (20080704), pages 446 - 450, (20080428), XP022670720 [T] 1-13 * The whole document, in particular; page 446, column 2, line 4 - line 8 *

DOI:   http://dx.doi.org/10.1016/j.bbrc.2008.04.110
Examination   - PIETSCHMANN T ET AL, "Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US LNKD- DOI:10.1073/PNAS.0504877103, (20060509), vol. 103, no. 19, ISSN 0027-8424, pages 7408 - 7413, XP002461116

DOI:   http://dx.doi.org/10.1073/pnas.0504877103
    - PIETSCHMANN T ET AL, "Persistent and transient replication of full-length hepatitis C virus genomes in cell culture", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US LNKD- DOI:10.1128/JVI.76.8.4008-4021.2002, (20020401), vol. 76, no. 8, ISSN 0022-538X, pages 4008 - 4021, XP002377301

DOI:   http://dx.doi.org/10.1128/JVI.76.8.4008-4021.2002
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.